[A20-08] Upadacitinib (rheumatoid arthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 16.07.2020
Commission awarded on 16.01.2020 by the Federal Joint Committee (G-BA).
Muscles, bones and joints
Adults with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to DMARDs
First treatment with bDMARDs or tsDMARDs indicated: for combination with MTX indication of considerable added benefit. Patients with high disease activity who have responded inadequately to, or who are intolerant to one or more bDMARDs and/or tsDMARDs: for combination with MTX indication of minor added benefit. Monotherapy and other patient groups: added benefit not proven.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2020-05-04.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
|A21-16||Upadacitinib (ankylosing spondylitis) - Benefit assessment according to §35a Social Code Book V||Commission completed|
|A21-15||Upadacitinib (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V||Commission completed|